# Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

> **NCT06841055** · PHASE2 · RECRUITING · sponsor: **BioNTech SE** · enrollment: 60 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Pumitamig
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT06841055
- **Lead sponsor:** BioNTech SE
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-03
- **Primary completion:** 2028-10
- **Final completion:** 2028-10
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06841055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06841055, "Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT06841055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*